Third Harmonic Bio Inc. (THRD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Third Harmonic Bio Inc. (THRD) has a cash flow conversion efficiency ratio of -0.049x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.48 Million) by net assets ($272.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Third Harmonic Bio Inc. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Third Harmonic Bio Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Third Harmonic Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Third Harmonic Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Third Harmonic Bio Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jasuindo Tiga Perkasa Tbk
JK:JTPE
|
-0.046x |
|
Gajah Tunggal Tbk
JK:GJTL
|
0.068x |
|
TTS (TRANSPORT TRADE SERVICES)
RO:TTS
|
0.023x |
|
Absolent Group AB
ST:ABSO
|
0.040x |
|
Nu Skin Enterprises Inc
NYSE:NUS
|
0.034x |
|
Sailfish Royalty Corp
V:FISH
|
0.020x |
|
Bank Net Indonesia Syariah Tbk PT
JK:BANK
|
0.194x |
|
ODFJELL TECHNOLOGYLTD
F:ND4
|
0.302x |
Annual Cash Flow Conversion Efficiency for Third Harmonic Bio Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Third Harmonic Bio Inc. from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see THRD market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $285.15 Million | $-34.50 Million | -0.121x | -59.41% |
| 2023-12-31 | $269.08 Million | $-20.43 Million | -0.076x | +37.16% |
| 2022-12-31 | $289.07 Million | $-34.92 Million | -0.121x | -135.83% |
| 2021-12-31 | $-46.71 Million | $-15.75 Million | 0.337x | -32.64% |
| 2020-12-31 | $-18.36 Million | $-9.19 Million | 0.500x | -- |
About Third Harmonic Bio Inc.
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibit… Read more